⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
businesswire.com
ARWR
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
prnewswire.com
DAY
ADT
OSW
DVAX
ARWR
CIEN
SPGI
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration
prnewswire.com
ALT
ARWR
MNKD
LCTX
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
businesswire.com
ARWR
Next Generation Drug Conjugates Market Trends and Global Forecasts, 2025-2035 - Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra Represent Milestones in Advanced Treatment Solutions - ResearchAndMarkets.com
businesswire.com
NVS
ALNY
ARWR
GERN
IONS
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
businesswire.com
ARWR
$15.5 Bn Next Generation Drug Conjugates Market Trends and Global Forecasts, 2035
globenewswire.com
ALNY
ARWR
GERN
IONS
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
globenewswire.com
AMGN
ARWR
IONS
NVS
NVO
MRK
LLY
REGN
ESPR
ALNY
VRTX
XBI
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
businesswire.com
ARWR
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO ® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
businesswire.com
ARWR